| scholarly article | Q13442814 |
| P50 | author | Vera Bittner | Q39525261 |
| Nanette Wenger | Q66087834 | ||
| John J. P. Kastelein | Q110410211 | ||
| P2093 | author name string | Daniel J Wilson | |
| Andrea Zuckerman | |||
| Prakash Deedwania | |||
| James Shepherd | |||
| Andrei Breazna | |||
| Stephen Dobson | |||
| TNT (Treating to New Targets) Investigators | |||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| heart disease | Q190805 | ||
| chronic renal insufficiency | Q736715 | ||
| coronary artery disease | Q844935 | ||
| P304 | page(s) | 1448-1454 | |
| P577 | publication date | 2008-04-01 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study | |
| P478 | volume | 51 |
| Q28301815 | 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines |
| Q58580165 | Adaptation of 2016 European Society of Cardiology/European Atherosclerosis Society guideline for lipid management to Indian patients - A consensus document |
| Q59926638 | Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction |
| Q37259275 | Association of preventive health care with atherosclerotic heart disease and mortality in CKD |
| Q37765562 | Atorvastatin: safety and tolerability |
| Q55512228 | Beneficial effect of statins in patients receiving chronic hemodialysis following percutaneous coronary intervention: A nationwide retrospective cohort study. |
| Q53494879 | Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. |
| Q38208727 | Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases. |
| Q37638675 | Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis |
| Q33908782 | Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SB |
| Q83854398 | Cardioprotective role of statins in chronic kidney disease: do we have the answer? |
| Q44358956 | Cardiovascular disease and chronic kidney disease: from treatment to promoting health |
| Q37454373 | Cardiovascular risk and management in chronic kidney disease |
| Q37557361 | Cardiovascular risk factors in patients with chronic kidney disease |
| Q33562172 | Carotid endarterectomy benefits patients with CKD and symptomatic high-grade stenosis |
| Q87393559 | Chapter 2: Pharmacological cholesterol-lowering treatment in adults |
| Q92919658 | Cholesterol-Lowering Treatment in Chronic Kidney Disease: Multistage Pairwise and Network Meta-Analyses |
| Q38262592 | Chronic kidney disease and cardiovascular complications |
| Q35664598 | Chronic kidney disease and coronary artery vulnerable plaques |
| Q37509290 | Chronic kidney disease and statins: improving cardiovascular outcomes. |
| Q43235425 | Chronic kidney disease as a predictor of coronary lesion morphology |
| Q51382088 | Chronic kidney disease as a risk factor for acute coronary syndromes in patients presenting to the emergency room with chest pain. |
| Q36482659 | Chronic kidney disease is associated with increased coronary artery atherosclerosis as revealed by multidetector computed tomographic angiography. |
| Q38020764 | Clinical assessment and management of dyslipidemia in patients with chronic kidney disease |
| Q30363683 | Clinical therapeutic strategies for early stage of diabetic kidney disease. |
| Q36943996 | Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease |
| Q35047636 | Deeper insight into chronic kidney disease-related atherosclerosis: comparative proteomic studies of blood plasma using 2DE and mass spectrometry. |
| Q33583018 | Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis |
| Q34429278 | Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes |
| Q35020237 | Dyslipidemia associated with chronic kidney disease |
| Q35667598 | Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial |
| Q33588706 | Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials |
| Q36005146 | Effects of Omega-3 Fatty Acid Supplementation on Diabetic Nephropathy Progression in Patients with Diabetes and Hypertriglyceridemia |
| Q37471756 | Effects of statin treatment in patients with coronary artery disease and chronic kidney disease |
| Q36077149 | Effects of statins on cardiorenal syndrome. |
| Q37880123 | Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis |
| Q37216924 | Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease |
| Q30651756 | Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001-2010. |
| Q37812387 | Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy |
| Q37873794 | Evidence-based statin prescription for cardiovascular protection in renal impairment. |
| Q24194514 | HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis |
| Q38726224 | Has cost inhibited the uptake of more potent statins in England? |
| Q26853061 | High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis |
| Q35691372 | IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis |
| Q45750535 | Impact of Statin Therapy on Renal Function and Long-Term Prognosis in Acute Coronary Syndrome Patients With Chronic Kidney Disease |
| Q51338547 | Impact of low-density lipoprotein cholesterol on decline in estimated glomerular filtration rate in apparently healthy young to middle-aged working men. |
| Q37704388 | Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy |
| Q37115852 | Improving evidence-based primary care for chronic kidney disease: study protocol for a cluster randomized control trial for translating evidence into practice (TRANSLATE CKD) |
| Q26866480 | Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets |
| Q93035489 | Investigating associated factors with glomerular filtration rate: structural equation modeling |
| Q38076216 | Is lipid management effective for all stages of CKD?. |
| Q35871962 | Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes? |
| Q58362346 | Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017 |
| Q37245464 | Kidney function and estimated vascular risk in patients with primary dyslipidemia |
| Q34579290 | Leveraging practice-based research networks to accelerate implementation and diffusion of chronic kidney disease guidelines in primary care practices: a prospective cohort study |
| Q37853015 | Lipid control in patients with diabetes mellitus |
| Q42688659 | Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease. |
| Q58561315 | Lipid management in patients with chronic kidney disease |
| Q42723918 | Low-density lipoprotein cholesterol reduction and prevention of cardiovascular disease |
| Q38082646 | Management of cardiovascular disease in patients with kidney disease |
| Q30238977 | Management of coronary artery disease and acute coronary syndrome in the chronic kidney disease population-A review of the current literature |
| Q89741990 | Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology |
| Q38878462 | Meta-analysis of statins in chronic kidney disease: who benefits? |
| Q35610709 | Mild and moderate pre-dialysis chronic kidney disease is associated with increased coronary artery calcium |
| Q35220442 | Moderate kidney disease inhibits atherosclerosis regression |
| Q37780943 | National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events |
| Q50154559 | National survey: Evaluation of cardiovascular risk factors in Thai patients with type 2 diabetes and chronic kidney disease after the development of cardiovascular disease |
| Q37642755 | Non-adherence to statin therapy: a major challenge for preventive cardiology |
| Q54977897 | Oxidative Stress, Apoptosis, and Mitochondrial Function in Diabetic Nephropathy. |
| Q36021782 | Pharmacological and non pharmacological strategies in the management of coronary artery disease and chronic kidney disease |
| Q89903377 | Pharmacological interventions for heart failure in people with chronic kidney disease |
| Q34019491 | Potential role of differential medication use in explaining excess risk of cardiovascular events and death associated with chronic kidney disease: a cohort study |
| Q35622817 | Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role? |
| Q90102183 | Prognostic Value of Hepatorenal Function By Modified Model for End-stage Liver Disease (MELD) Score in Patients Undergoing Tricuspid Annuloplasty |
| Q34985796 | Reasons for discontinuation of lipid-lowering medications in patients with chronic kidney disease |
| Q34887952 | Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus |
| Q37335055 | Reducing lipids for CV protection in CKD patients-current evidence |
| Q54203490 | Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events? |
| Q93609057 | References |
| Q35571854 | Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy |
| Q38372669 | Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge |
| Q36931219 | Simvastatin ameliorates ventricular remodeling via the TGF‑β1 signaling pathway in rats following myocardial infarction |
| Q35690546 | Stage A Heart Failure Is Not Adequately Recognized in US Adults: Analysis of the National Health and Nutrition Examination Surveys, 2007-2010 |
| Q35232279 | Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel |
| Q38365428 | Statin use after acute myocardial infarction by patient complexity: are the rates right? |
| Q37807332 | Statins and Renal Disease: Friend or Foe? |
| Q36984049 | Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study |
| Q53645752 | Statins and mortality: the untold story. |
| Q38513740 | Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? |
| Q38176142 | Statins in chronic kidney disease: cardiovascular risk and kidney function |
| Q37803236 | Statins in patients with chronic kidney disease: why, who and when? |
| Q37883015 | Statins, inflammation and kidney disease |
| Q35675305 | Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation |
| Q26852726 | Targeting inflammation in diabetes: Newer therapeutic options |
| Q33571353 | Therapeutic management in patients with renal failure who experience an acute coronary syndrome |
| Q48020713 | Treat-to-target lipid control is effective but highlighted poor prognosis without indication of statin following percutaneous coronary intervention |
| Q38553332 | Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy |
| Q46073252 | Urinary NGAL-Positive Acute Kidney Injury and Poor Long-term Outcomes in Hospitalized Patients |
| Q33984593 | Use of statin therapy to reduce cardiovascular risk in older patients |
| Q38268914 | What the guidelines do not say: statin non-benefit groups |
| Q84290516 | [Cardiovascular disease, renal disease and other chronic diseases. Earlier intervention is needed in chronic renal disease] |
| Q83879580 | [Renal function in heart failure patients. Prognostic influence and therapeutic implications] |
Search more.